EMA Panel Denies Abaloparatide for Osteoporosis
The marketing application for abaloparatide – a subcutaneous injection developed by Radius Health for the treatment of osteoporosis in post-menopausal women – has been rejected by the Committee for Medicinal Products for Human Use (CHMP), a scientific committee of the European Medicines Agency (EMA).